• 1
    Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer 2006;42:167183.
  • 2
    Gulbrandsen N, Hjermstad MJ, Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004;72:17280.
  • 3
    Levine MN, Ganz PA. Beyond the development of quality-of-life instruments: where do we go from here? J Clin Oncol 2002;20:22156.
  • 4
    Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 2000;53:4518.
  • 5
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:37183.
  • 6
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:40715.
  • 7
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:13944.
  • 8
    Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008;44:14971506.
  • 9
    Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials – does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:350211.
  • 10
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:65762.
  • 11
    Bottomley A, Efficace F, Fayers PM. Standards are needed for quality of life clinical trials. BMJ 2002;324:1156.
  • 12
    Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996;5:496502.
  • 13
    Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:41051.
  • 14
    Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 2003;4:37998.
  • 15
    Lokhorst H, Huijgens PC, Raymakers R, Bos GM, Vellenga E, Wijermans PW, Sonneveld P. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd 2005;149:80813.
  • 16
    Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19:ii557.
  • 17
    Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2007;22:2319.
  • 18
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:48893.
  • 19
    Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:1729.
  • 20
    Joshua DE, Penny R, Matthews JP, Laidlaw CR, Gibson J, Bradstock K, Wolf M, Goldstein D. Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol 1997;97:3845.
  • 21
    Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 2008;143:5119.
  • 22
    Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:23539.
  • 23
    Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:20512.
  • 24
    Schaar CG, Kluin-Nelemans HC, Te MC, Le CS, Breed WP, Fibbe WE, Van Deijk WA, Fickers MM, Roozendaal KJ, Wijermans PW. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005;16:6349.
  • 25
    Segeren CM, Sonneveld P, Van Der HB, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:214451.
  • 26
    Sirohi B, Powles R, Lawrence D, Treleaven J, Kulkarni S, Leary A, Rudin C, Horton C, Morgan G. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b. Ann Oncol 2007;18:138894.
  • 27
    Smith AG, Soutar RL, Schey S, Andrews CD, Baister ER, Bilbrough C, Connelly M, Joyce A, Child JA. Home care versus hospital care in patients with multiple myeloma treated with pamidronate. Int J Palliat Nurs 2004;10:1449.
  • 28
    Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996;94:32432.
  • 29
    Hedenus M, Adriansson M, San MJ, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394403.
  • 30
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:286574.
  • 31
    Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002;20:248694.
  • 32
    Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 2006;107:190917.
  • 33
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:36576.
  • 34
    Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:139.
  • 35
    Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996;92:60413.
  • 36
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:47383.
  • 37
    Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:54761.
  • 38
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:248798.
  • 39
    Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 2007;18:77581.
  • 40
    Ludwig H, Fritz E. Interferon in multiple myeloma – summary of treatment results and clinical implications. Acta Oncol 2000;39:81521.
  • 41
    Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002;4:CD003188.
  • 42
    Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:104753.
  • 43
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:917.
  • 44
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:187583.
  • 45
    Attal M, Harousseau JL. Role of autologous stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2007;20:74759.
  • 46
    Stead ML, Brown JM, Velikova G, Kaasa S, Wisloff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999;104:60511.
  • 47
    Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:16708.
  • 48
    Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000;18:41923.
  • 49
    Fayers PM, Machin D. Quality of Life: The Assessment, analysis, and Interpretation of Patient-reported Outcomes. Chichester: J. Wiley, 2007.